It is a known fact that diagnostics plays a vital role in deciding the course of medication – be it drugs or a long-term therapy. However, with upsurge in several diseases attacking the bodies of living beings, the approach of “one size fits all” can’t be followed. Specificity is the need of the hour.
Influenza, which seems to be “common cold” in general parlance, is much more than that. These days, several ailments are found to have their roots in influenza. As such, there are numerous tests available to distinguish the influenza diagnostics market. They are molecular (RT-PCR, NASBA, LAMP) and conventional (serological assays, rapid influenza detection tests, direct fluorescent antibody, and viral culture).
Out of these, rapid influenza detection tests are ruling the roots, as diagnoses of flu is of utmost importance, especially with the fact that seasonal flu is caught by majority of the Americans atleast once a year. The other regions are also not behind. So, it could be inferred that the rapid influenza diagnostics market will witness a major overhaul in the forecast period. On the whole, influenza diagnostics market won’t be looking back in terms of revenue generation going forward.
Delving deeper, we get to know that there are the other infectious diseases hovering. They include TB, HPV, HAI, HIV, and Hepatitis. There are molecular diagnostics techniques used. Apart from HIV, TB and Hepatitis, they help in detecting MRSA (Methicillin-Resistant Staphylococcus Aureus) hospital-acquired infections, CT/NG (Chlamydia Trachomatis and Neisseria Gonorrhoeae) as well.
The techniques falling in this category include INAAT (Isothermal Nucleic Acid Amplification Technology), PCR (Polymerase Chain Reaction), NGS (next-generation sequencing), microarrays, and hybridization. The players operating in molecular diagnostics infectious disease testing include Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Abbott Laboratories, Luminex Corp., Genomix Biotech, GenMark Diagnostics, Veridex, LLC, Siemens AG, F. Hoffmann-La Roche Ltd., and bioTheranostics.
These days there are Point-of-Care Infectious disease Diagnostics available and preferred by low-income countries due to being low-cost and precise. Point-of-Care Infectious Disease Diagnostics Market is bound to flourish side-by-side, with nano-diagnostics proving to be the epicentre.
Persistence Market Research (PMR) has mapped the entire market region-wise into North America, Europe, the Asia-Pacific, LATAM, and MEA. It has gone further stating that North America is the flag bearer to drug diagnostics, followed by Europe. In future, the Asia-Pacific is expected to take over with people becoming more aware about the need for early and proper diagnostics.
The millennials herein do not take something like “cold” this lightly. Also, the ongoing pandemic has compelled them as well as the others to take these ailments seriously. This thought process is captured by PMR in its market study on Drugs and Diagnostics.
Coming back to Point-of-Care Diagnostics, Persistence Market Research has stated that Thermo Fisher Scientific, in March 2020, did partner with QIAGEN N.V. for expanding the portfolio of diagnostics with a broad range of molecular diagnostic testing techniques. F. Hoffmann-La Roche Ltd., in May 2019, did launch CE-IVD Cobas MTB-RIF/INH test for detecting resistance with respect to antibiotics, that too, within TB DNA.
Global Market Study on Influenza Diagnostics: Increasing Availability of Rapid Influenza Diagnostic Tests Aiding Market GrowthRequest Sample